Physician profile
Amber N Smith
NPI 1275008609
$7,185.20
in general payments reported to CMS, 2019-2025
50 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $865 · 2023: $671 · 2024: $2,202 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,814 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,814.31 |
| Education | $121.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.69 | 2021-2025 | |
| Janssen Biotech, INC. | $640.92 | 2024-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $528.34 | 2024-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $444.86 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $409.34 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $397.59 | 2024-2025 | Zenpep |
| Urovant Sciences INC | $299.67 | 2021-2022 | |
| Pfizer INC. | $281.57 | 2023-2025 | |
| Gilead Sciences, INC. | $197.78 | 2024-2025 | Trodelvy |
| Madrigal Pharmaceuticals | $155.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $142.28 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $140.15 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $126.24 | 2024-2025 | Omvoh |
| Bayer Healthcare Pharmaceuticals INC. | $118.80 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $101.24 | 2022-2023 | Prolaris |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $98.11 | 2022-2023 | Urolift |
| Sumitomo Pharma America, INC. | $90.04 | 2023 | Gemtesa, Orgovyx |
| Ardelyx, INC. | $89.13 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $88.13 | 2021 | |
| Merck Sharp & Dohme LLC | $82.44 | 2023-2024 | Dificid, Keytruda, Welireg |
| Celltrion USA INC. | $81.45 | 2024-2025 | Vegzelma, Zymfentra |
| C. R. Bard, INC. & Subsidiaries | $73.91 | 2021-2023 | Bard Urinary Drainage Bag |
| 180 Medical, INC. | $71.74 | 2022-2023 | Gentlecath |
| Tolmar Pharmaceuticals, INC. | $70.01 | 2022 | |
| Ironwood Pharmaceuticals, INC | $66.91 | 2024-2025 | |
| Novo Nordisk INC | $57.53 | 2025 | Wegovy |
| Tolmar, INC. | $54.24 | 2023 | |
| Glaxosmithkline, LLC. | $53.73 | 2022-2025 | Arexvy, Shingrix |
| Braintree Laboratories, INC. | $50.86 | 2025 | Suflave |
| Myovant Sciences INC. | $48.68 | 2022 | |
| Medtronic, INC. | $42.33 | 2023 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.19 | 2024 | Cyltezo |
| Blue Earth Diagnostics | $40.69 | 2023 | |
| Progenics Pharmaceuticals, INC. | $40.20 | 2023 | Pylarify |
| Ambu INC. | $39.65 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $36.55 | 2023 | Seglentis |
| Convatec INC. | $36.53 | 2023 | |
| Boston Scientific Corporation | $35.92 | 2023-2024 | Lumenis Pulse 120h |
| Mauna Kea Technologies, INC. | $24.07 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.68 | 2025 | Givlaari |
| Urogen Pharma, INC. | $22.70 | 2023 | Jelmyto |
| Intercept Pharmaceuticals, INC. | $22.13 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.61 | 2024 | Bylvay |
| Allergan, INC. | $20.25 | 2022 | |
| Abc Home Medical Supply, INC. | $19.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.79 | 2022 | |
| Photocure INC | $16.14 | 2023 | Cysview |
| Evoke Pharma, INC. | $16.01 | 2025 | |
| Dynavax Technologies Corporation | $14.56 | 2024 | Heplisav-B |
| Hollister Incorporated | $13.03 | 2023 | Vapro Pocket, Vapro, Infyna Chic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.